GSTM1 and pulmonary arterial hypertension: There is one study showing that glutathione S-transferase mu1 (GSTM1) was significantly decreased in the irreversible CHD-PAH patients, suggesting GSTM1 may be a potential biomarker and target in the irreversibility CHD-PAH (Huang et al., 2018).